Literature DB >> 25141576

Homocysteine in patients with inflammatory bowel diseases.

Danuta Owczarek, Dorota Cibor, Kinga Sałapa, Artur Jurczyszyn, Tomasz Mach.   

Abstract

BACKGROUND: Hyperhomocysteinemia seems to be a common phenomenon in both patients with ulcerative colitis and Crohn's disease. Many factors including deficiencies of cobalamin, folate and pyridoxine, smoking habits, alcohol and coffee intake, some medications and age may predispose subjects to hyperhomocysteinemia. The study aimed to evaluate homocysteine levels in an inflammatory bowel disease cohort as dependent of life style and disease activity.
METHODS: 85 consecutive patients with inflammatory bowel disease (38 with Crohn's disease and 47 with ulcerative colitis) and 65 control subjects were included in the prospective study. The following parameters were analyzed: disease activity, duration of the disease, location of pathological changes, presence of complications, current medications, past surgical procedures, smoking history, concomitant diseases, biochemical parameters and plasma homocysteine levels.
RESULTS: Mild hyperhomocysteinemia was found in 16 patients with Crohn's disease (42%), 19 patients with ulcerative colitis (40%) and 19 patients in the control group (29%) (p = 0.59). There was not any significant correlation between homocysteine level and disease activity. Only folic acid supplementation and gender affected homocysteine level. Folic acid intake led to reduction of homocysteine levels in all groups of patients (11.8 micromol/l vs. 8.33 miccromol/l, p = 0.0065 in Crohn's disease patients and 10.94 micromol/l vs. 7.78 micromol/l, p = 0.0069 in ulcerative colitis patients).
CONCLUSION: Homocysteine level in patients with inflammatory bowel disease is mostly normal or slightly elevated. Disease activity does not have an impact on homocysteine level. Folic acid is the most important factor having an influence on homocysteine level in patients with inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25141576

Source DB:  PubMed          Journal:  Przegl Lek        ISSN: 0033-2240


  4 in total

Review 1.  Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications.

Authors:  Dorota Cibor; Renata Domagala-Rodacka; Tomasz Rodacki; Artur Jurczyszyn; Tomasz Mach; Danuta Owczarek
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

2.  Association between serum folate with inflammatory markers, disease clinical activity and serum homocysteine in patients with inflammatory bowel disease. Does folate level have an effect on maintaining clinical remission?

Authors:  Soheila Moein; Mostafa Vaghari-Tabari; Durdi Qujeq; Mehrdad Kashifard; Javad Shokri-Shirvani; Karimollah Hajian-Tilaki
Journal:  Acta Biomed       Date:  2020-11-10

Review 3.  Does Folic Acid Protect Patients with Inflammatory Bowel Disease from Complications?

Authors:  Alicja Ewa Ratajczak; Aleksandra Szymczak-Tomczak; Anna Maria Rychter; Agnieszka Zawada; Agnieszka Dobrowolska; Iwona Krela-Kaźmierczak
Journal:  Nutrients       Date:  2021-11-12       Impact factor: 5.717

4.  Serum Homocysteine Concentration Is Significantly Associated with Inflammatory/Immune Factors.

Authors:  Tianyu Li; Yang Chen; Jie Li; Xiaobo Yang; Haiying Zhang; Xue Qin; Yanling Hu; Zengnan Mo
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.